DOCSLIB.ORG

Dystonia”[Mesh] OR Dystonia[Tiab] OR “Torticollis”[Mesh] OR Torticollis[Tiab]

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Dystonia”[Mesh] OR Dystonia[Tiab] OR “Torticollis”[Mesh] OR Torticollis[Tiab] eAppendix 1: Search Strategy The PubMed search strategy employed the following terms (yielded 910 hits on 3/28/17): (“Dystonia”[Mesh] OR dystonia[tiab] OR “Torticollis”[Mesh] OR torticollis[tiab] OR wryneck[tiab] OR "Psychomotor Agitation"[Mesh] OR “psychomotor agitation”[tiab] OR restlessness[tiab] OR akathisia[tiab] OR "Akathisia, Drug-Induced"[Mesh] OR “drug-induced akathisia”[tiab] OR “tardive akathisia”[tiab] OR “Hypokinesia”[Mesh] OR hypokinesia[tiab] OR hypodynamia[tiab] OR bradykinesia[tiab] OR “Tardive Dyskinesia”[Mesh] OR “tardive dyskinesia”[tiab] OR "Drug-Related Side Effects and Adverse Reactions"[Mesh] OR “adverse drug event”[tiab] OR “adverse drug reaction”[tiab] OR “drug side effect”[tiab] OR "Treatment Outcome"[Mesh] OR “treatment outcome”[tiab]) AND ("Diphenhydramine"[Mesh] OR Diphenhydramine[tiab] OR "Histamine H1 Antagonists"[Mesh] OR “Histamine H1 Antagonists”[tiab] OR "Histamine H1 Antagonists" [Pharmacological Action] OR "Benztropine"[Mesh] OR benztropine[tiab]) AND ("Dopamine D2 Receptor Antagonists"[Mesh] OR “dopamine D2 antagonists”[tiab] OR "Dopamine D2 Receptor Antagonists" [Pharmacological Action] OR "Antiemetics"[Mesh] OR antiemetics[tiab] OR "Antiemetics" [Pharmacological Action] OR "Metoclopramide"[Mesh] OR metoclopramide[tiab] OR "Prochlorperazine"[Mesh] OR prochlorperazine[tiab] OR “Chlorpromazine” [MeSH] OR chlorpromazine[tiab] OR "Cholinergic Antagonists"[Mesh] OR “cholinergic antagonists”[tiab] OR "Cholinergic Antagonists" [Pharmacological Action] OR "Droperidol"[Mesh] OR droperidol[tiab]) The Cochrane search strategy employed the following terms (yielded 143 hits on 3/24/17): 1. (search terms 1 to 7): Dystonia, hypokinesia, extrapyramidal rigidity, psychomotor agitation, movement disorders, Drug-Related Side Effects and Adverse Reactions, treatment outcome 2. (search terms 8 to 10) Diphenhydramine, Histamine H1 Antagonists, Benztropine 3. (search terms 11 to 17) Dopamine D2 Receptor Antagonists, Antiemetics, Metoclopramide, Prochlorperazine, Chlorpromazine, Cholinergic Antagonists, Droperidol 4. Search strategy: (#1 or #2 or #3 or #4 or #5 or #6 or #7) and (#8 or #9 or #10) and (#11 or #12 or #13 or #14 or #15 or #16 or #17) The Embase search strategy employed the following terms (yielded 542 hits on 3/24/17): ‘extrapyramidal symptom’/exp OR ‘restlessness’/exp OR ‘psychomotor disorder’/exp OR ‘parkinsonism’/exp OR ‘tardive dyskinesia’/exp OR ‘adverse drug reaction’/exp OR ‘treatment outcome’/exp AND ‘diphenhydramine’/exp OR ‘Histamine H1 receptor Antagonists’/exp OR ‘benzatropine’/exp AND ‘dopamine 2 receptor blocking agent’/exp OR ‘Antiemetic agent’/exp OR ‘cholinergic receptor blocking agent’/exp) The Web of Science search strategy employed the following terms (yielded 36 hits on 3/28/17): #1 search: (TS=(dystonia OR torticollis OR "psychomotor agitation" OR restlessness OR akathisia OR "Drug-Induced Akathisia" OR hypokinesia OR "tardive dyskinesia" OR "Adverse Drug Event" OR "Adverse Drug Reaction" OR EPS OR "extrapyramidal symptoms")) #2 search: TS=(diphenhydramine OR "Histamine H1 Antagonists" OR benzatropine OR benztropine) #3 search: TS=("Dopamine D2 Receptor Antagonists" OR antiemetics OR metoclopramide OR prochlorperazine OR chlorpromazine OR "Cholinergic Antagonists" OR droperidol ) Combined search: #3 AND #2 AND #1 AND LANGUAGE: (English) AND DOCUMENT TYPES: (Article) All years Core collection (SCI-EXPANDED & SSCI) The Scopus search strategy employed the following terms (yielded 906 hits on 3/28/17): (TITLE-ABS-KEY ( dystonia OR torticollis OR "psychomotor agitation" OR restlessness OR "Drug-Induced Akathisia" OR hypokinesia OR akathisia OR EPS OR "extrapyramidal symptoms" OR "Adverse Drug Event" OR "Adverse Drug Reaction" ) AND TITLE-ABS-KEY ( diphenhydramine OR "Histamine H1 Antagonists" OR benzatropine OR benztropine ) AND TITLE-ABS-KEY ( "Dopamine D2 Receptor Antagonists" OR antiemetics OR metoclopramide OR prochlorperazine OR chlorpromazine OR "Cholinergic Antagonists" OR droperidol ) ) AND ( LIMIT-TO ( SRCTYPE,"j " ) ) AND ( LIMIT-TO ( DOCTYPE,"ar " ) OR LIMIT-TO ( DOCTYPE,"cp " )).
Load more

Recommended publications
  • Acute Extrapyramidal Symptoms Following Abrupt Discontinuation of Propranolol
    Medical Journal of the Volume 14 Islamic Republic of Iran Number 3 Fall 1379 November 2000 ACUTE EXTRAPYRAMIDAL SYMPTOMS FOLLOWING ABRUPT DISCONTINUATION OF PROPRANOLOL A. ALAVIAN GHAVANINI From the Center Jor Research Consultation, School oj Medicine, Shiraz University ojMedical Sciences, Shiraz, I.R. Iran. ABSTRACT A case of acute extrapyramidal manifestations consisting of dystonia and akathisia following abrupt discontinuation of propranolol is reported. She re­ sponded well to oral propranolol and intramuscular diazepam. Extrapyramidal symptoms have commonly been associated with acute or chronic administration of neuroleptic drugs. There have been reports of a substantial number of cases with similar clinical characteristics associated with tricyclic antidepressants, monoamine oxidase inhibitors, and selective serotonin reuptake inhibitors. Al­ though it is known that beta-adrenoceptor antagonists are effective in the treat­ ment of extrapyramidal symptoms, especially akathisia, there has been no previ­ ous report of such symptoms induced by abrupt withdrawal of these drugs. Al­ though she had been on low dose amitriptyline and had discontinued this medica­ tion long before, prolonged use of amitriptyline may have had a predisposing role in the development of these symptoms. MJIRL Vol. 14, No.3, 305-306, 2000. Keywords: Propranolol; Extrapyramidal symptoms; Beta-adrenoceptor antagonists. INTRODUCTION She described a feeling of "being pulled down by gravity." She had never experienced such symptoms before. Thor­ Extrapyramidal symptoms include acute dystonias, ough physical examination with special focus on the ner­ akathisia, Parkinson's syndrome, and tardive dyskinesia. vous system was unremarkable except for the involuntary These symptoms are common manifestations of neurolep­ contraction of jaw muscles and a fine tremor in her ex­ tic drugs.
    [Show full text]
  • Prevalence of Extrapyramidal Side Effects in Patients on Antipsychotics Drugs at a Tertiary Care Center
    f Ps al o ych rn ia u tr o y J Kirgaval et al., J Psychiatry 2017, 20:5 Journal of Psychiatry DOI: 10.4172/2378-5756.1000419 ISSN: 2378-5756 Research Article Open Access Prevalence of Extrapyramidal Side Effects in Patients on Antipsychotics Drugs at a Tertiary Care Center5 Ramprasad Santhanakrishna Kirgaval1*, Srinivas Revanakar2 and Chidanand Srirangapattna2 1Department of Psychiatry, Shimoga Institute of Medical Sciences, Shimoga, Karnataka, India 2Department of Pharmacology, Shimoga Institute of Medical Sciences, Shimoga, Karnataka, India Abstract Background: Antipsychotic drugs are associated with adverse effects that can lead to poor medication adherence, stigma, distress and impaired quality of life. Among the various side effects of anti-psychotics extra pyramidal symptoms constitute one of the important side effects interfering with the compliance of the patients towards medication. Objective: Evaluation of extrapyramidal side effects by AIMS in patients who are on antipsychotics. Results: The extrapyramidal symptoms were more commonly seen in males (62.85%), the age of incidence of maximum in the age group of 34.28, Maximum was seen among the patients on the Risperidone (45.7%), Involvement of the extremities was common (42.85%) and 64.28% of individuals had moderate severity and 54.28% of individuals were aware of the extrapyramidal symptoms which provided mild distress. Conclusion: Extrapyramidal symptoms are one of the commonest side effect of the antipsychotics interfering with compliance of the patients towards adherence to medications, thereby decreasing the efficacy. Keywords: Extrapyramidal symptoms; Compliance; Antipsychotics; positive symptom of the psychosis but have some serious limitations AIMS. such as lack of efficacy against negative symptoms and adverse effects like extrapyramidal symptoms [7].
    [Show full text]
  • The In¯Uence of Medication on Erectile Function
    International Journal of Impotence Research (1997) 9, 17±26 ß 1997 Stockton Press All rights reserved 0955-9930/97 $12.00 The in¯uence of medication on erectile function W Meinhardt1, RF Kropman2, P Vermeij3, AAB Lycklama aÁ Nijeholt4 and J Zwartendijk4 1Department of Urology, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands; 2Department of Urology, Leyenburg Hospital, Leyweg 275, 2545 CH The Hague, The Netherlands; 3Pharmacy; and 4Department of Urology, Leiden University Hospital, P.O. Box 9600, 2300 RC Leiden, The Netherlands Keywords: impotence; side-effect; antipsychotic; antihypertensive; physiology; erectile function Introduction stopped their antihypertensive treatment over a ®ve year period, because of side-effects on sexual function.5 In the drug registration procedures sexual Several physiological mechanisms are involved in function is not a major issue. This means that erectile function. A negative in¯uence of prescrip- knowledge of the problem is mainly dependent on tion-drugs on these mechanisms will not always case reports and the lists from side effect registries.6±8 come to the attention of the clinician, whereas a Another way of looking at the problem is drug causing priapism will rarely escape the atten- combining available data on mechanisms of action tion. of drugs with the knowledge of the physiological When erectile function is in¯uenced in a negative mechanisms involved in erectile function. The way compensation may occur. For example, age- advantage of this approach is that remedies may related penile sensory disorders may be compen- evolve from it. sated for by extra stimulation.1 Diminished in¯ux of In this paper we will discuss the subject in the blood will lead to a slower onset of the erection, but following order: may be accepted.
    [Show full text]
  • Modern Antipsychotic Drugs: a Critical Overview
    Review Synthèse Modern antipsychotic drugs: a critical overview David M. Gardner, Ross J. Baldessarini, Paul Waraich Abstract mine was based primarily on the finding that dopamine ago- nists produced or worsened psychosis and that antagonists CONVENTIONAL ANTIPSYCHOTIC DRUGS, used for a half century to treat were clinically effective against psychotic and manic symp- a range of major psychiatric disorders, are being replaced in clini- 5 toms. Blocking dopamine D2 receptors may be a critical or cal practice by modern “atypical” antipsychotics, including ari- even sufficient neuropharmacologic action of most clinically piprazole, clozapine, olanzapine, quetiapine, risperidone and effective antipsychotic drugs, especially against hallucina- ziprasidone among others. As a class, the newer drugs have been promoted as being broadly clinically superior, but the evidence for tions and delusions, but it is not necessarily the only mecha- this is problematic. In this brief critical overview, we consider the nism for antipsychotic activity. Moreover, this activity, and pharmacology, therapeutic effectiveness, tolerability, adverse ef- subsequent pharmacocentric and circular speculations about fects and costs of individual modern agents versus older antipsy- altered dopaminergic function, have not led to a better un- chotic drugs. Because of typically minor differences between derstanding of the pathophysiology or causes of the several agents in clinical effectiveness and tolerability, and because of still idiopathic psychotic disorders, nor have they provided a growing concerns about potential adverse long-term health conse- non-empirical, theoretical basis for the design or discovery quences of some modern agents, it is reasonable to consider both of improved treatments for psychotic disorders. older and newer drugs for clinical use, and it is important to inform The neuropharmacodynamics of specific modern anti- patients of relative benefits, risks and costs of specific choices.
    [Show full text]
  • Journal of Pharmaceutical and Pharmacological Sciences Jaithliya T
    Journal of Pharmaceutical and Pharmacological Sciences Jaithliya T. J Pharma Pharma Sci 02: JPPS 122. Case Report DOI:10.29011/2574-7711.100022 Ashwagandha-The Nature’s Gift to Mankind Tanvay Jaithliya* Department of Pharmacy, Mewar University, Gangrar (Chittorgarh), India *Corresponding author: Jaithliya T, Department of Pharmacy, Mewar University, Gangrar (Chittorgarh) India. Tel: +91 01471291148; E-mail: [email protected] Citation: Jaithliya T (2017) Ashwagandha-The Nature’s Gift to Mankind. J Pharma Pharma Sci 02: 122. DOI: 10.29011/2574-7711.100022 Received Date: 15 March, 2017; Accepted Date: 10 April, 2017; Published Date: 17 April, 2017 Withania somnifera commonly known as Ashwagandha, In- Sindh, Gujarat and Rajasthan. It is also found in Nepal, China and dian Ginseng, poison gooseberry or winter cherry is a plant in the Yemen. solanaceae family or night shade family. It is used as one of the most powerful herbs in Ayurvedic healing, has been used since ancient times for a wide variety of conditions, and is most well- known for its restorative benefits. Traditionally, it is believed that a person who consumes this herbal medicine will gain horse like strength and vitality. Pathology Ashwagandha is prone to several pests and diseases. Leaf spot disease caused by alternariaalternata Is the most prevalent disease, which is most severe in the plains of Punjab, Haryana, Jammu and Kashmir and Himachal Pradesh? Bio deterioration of its pharmaceutically active components during leaf spot disease Description has been reported. This species is short, tender perennial shrub growing 14-30 Culinary Use inches tall. Leaves are dull green, elliptic, usually up to 10-12 cm long.
    [Show full text]
  • Partial Agreement in the Social and Public Health Field
    COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies, and superseding Resolution AP (82) 2) AND APPENDIX I Alphabetical list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 1 July 1988 APPENDIX II Pharmaco-therapeutic classification of medicines appearing in the alphabetical list in Appendix I updated to 1 July 1988 RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (superseding Resolution AP (82) 2) (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands and the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland, Spain and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969, 21 April 1988 and 5 May 1964, respectively, Considering that the aim of the Council of Europe is to achieve greater unity between its members and that this
    [Show full text]
  • Monoamine Reuptake Inhibitors in Parkinson's Disease
    Hindawi Publishing Corporation Parkinson’s Disease Volume 2015, Article ID 609428, 71 pages http://dx.doi.org/10.1155/2015/609428 Review Article Monoamine Reuptake Inhibitors in Parkinson’s Disease Philippe Huot,1,2,3 Susan H. Fox,1,2 and Jonathan M. Brotchie1 1 Toronto Western Research Institute, Toronto Western Hospital, University Health Network, 399 Bathurst Street, Toronto, ON, Canada M5T 2S8 2Division of Neurology, Movement Disorder Clinic, Toronto Western Hospital, University Health Network, University of Toronto, 399BathurstStreet,Toronto,ON,CanadaM5T2S8 3Department of Pharmacology and Division of Neurology, Faculty of Medicine, UniversitedeMontr´ eal´ and Centre Hospitalier de l’UniversitedeMontr´ eal,´ Montreal,´ QC, Canada Correspondence should be addressed to Jonathan M. Brotchie; [email protected] Received 19 September 2014; Accepted 26 December 2014 Academic Editor: Maral M. Mouradian Copyright © 2015 Philippe Huot et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The motor manifestations of Parkinson’s disease (PD) are secondary to a dopamine deficiency in the striatum. However, the degenerative process in PD is not limited to the dopaminergic system and also affects serotonergic and noradrenergic neurons. Because they can increase monoamine levels throughout the brain, monoamine reuptake inhibitors (MAUIs) represent potential therapeutic agents in PD. However, they are seldom used in clinical practice other than as antidepressants and wake-promoting agents. This review article summarises all of the available literature on use of 50 MAUIs in PD. The compounds are divided according to their relative potency for each of the monoamine transporters.
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • Psychiatric Effects of Drugs for Other Disorders
    TREATMENT STRATEGIES Psychiatric effects of drugs What’s new? for other disorders • Rimonabant, a cannabinoid CB1 receptor antagonist, is effective for weight loss in obesity but carries a 2.5-fold risk C Heather Ashton of depression and a threefold risk of anxiety compared with placebo • Nabilone, a synthetic cannabinoid receptor agonist similar to tetrahydrocannabinol (THC), and sativex, a plant- derived agent containing THC and cannabidiol, alleviate pain in spastic disorders and neuropathic pain; psychiatric Abstract side-effects are minimized by using modest doses and/or Many drugs used therapeutically for non-psychiatric disorders can cause combination with opioids or other analgesics neuropsychiatric reactions. A wide range of such effects are reported including sedation, sleep disturbance, anxiety, depression, mania, psy- • Abrupt withdrawal of baclofen may cause serious psychiatric chosis, cognitive disturbance and delirium. The reactions are usually reactions, especially delirium, and after chronic use the drug dose-related but may occur at therapeutic doses or on drug withdrawal should be withdrawn gradually over several weeks after chronic use. They are more common in elderly or ill patients or those with a psychiatric history and may be unpredictable or paradoxi- • Isotretinoin has not been shown to increase the risk of cal. Some of the more common psychiatric effects of drugs used for depression or suicide in adolescents treated for severe acne non-psychiatric disorders are reviewed briefly here. They include, among but remains under suspicion of causing rare paradoxical others, dopaminergic and antimuscarinic drugs for parkinsonism; digi- reactions talis and β-adrenoceptor antagonists for cardiovascular disorders; can- nabinoid receptor antagonists for obesity; corticosteroids for endocrine disorders, asthma and allergic conditions; and anti-infective drugs for bacterial, parastic and viral infections.
    [Show full text]
  • Acute Laryngeal Dystonia
    Collins N, Sager J. J Neurol Neuromedicine (2018) 3(1): 4-7 Neuromedicine www.jneurology.com www.jneurology.com Journal of Neurology & Neuromedicine Mini Review Open Access Acute laryngeal dystonia: drug-induced respiratory failure related to antipsychotic medications Nathan Collins*, Jeffrey Sager Santa Barbara Cottage Hospital Department of Internal Medicine Santa Barbara, CA, USA Article Info ABSTRACT Article Notes Acute laryngeal dystonia (ALD) is a drug-induced dystonic reaction that can Received: December 10, 2017 lead to acute respiratory failure and is potentially life-threatening if unrecognized. Accepted: January 16, 2018 It was first reported in 1978 when two individuals were noticed to develop *Correspondence: difficulty breathing after administration of haloperidol. Multiple cases have since Dr. Nathan Collins MD been reported with the use of first generation antipsychotics (FGAs) and more Santa Barbara Cottage Hospital recently second-generation antipsychotics (SGAs). Acute dystonic reactions (ADRs) Department of Internal Medicine, Santa Barbara, CA, USA, have an occurrence rate of 3%-10%, but may occur more frequently with high Email: [email protected] potency antipsychotics. Younger age and male sex appear to be the most common risk factors, although a variety of metabolic abnormalities and illnesses have also © 2018 Collins N. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License been associated with ALD as well. The diagnosis of ALD can go unrecognized as other causes of acute respiratory failure are often explored prior to ALD. The exact mechanism for ALD remains unclear, yet evidence has shown a strong correlation with extrapyramidal symptoms (EPS) and dopamine receptor blockade.
    [Show full text]
  • Review Article Monoamine Reuptake Inhibitors in Parkinson's Disease
    Review Article Monoamine Reuptake Inhibitors in Parkinson’s Disease Philippe Huot,1,2,3 Susan H. Fox,1,2 and Jonathan M. Brotchie1 1 Toronto Western Research Institute, Toronto Western Hospital, University Health Network, 399 Bathurst Street, Toronto, ON, Canada M5T 2S8 2Division of Neurology, Movement Disorder Clinic, Toronto Western Hospital, University Health Network, University of Toronto, 399BathurstStreet,Toronto,ON,CanadaM5T2S8 3Department of Pharmacology and Division of Neurology, Faculty of Medicine, UniversitedeMontr´ eal´ and Centre Hospitalier de l’UniversitedeMontr´ eal,´ Montreal,´ QC, Canada Correspondence should be addressed to Jonathan M. Brotchie; [email protected] Received 19 September 2014; Accepted 26 December 2014 Academic Editor: Maral M. Mouradian Copyright © 2015 Philippe Huot et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The motor manifestations of Parkinson’s disease (PD) are secondary to a dopamine deficiency in the striatum. However, the degenerative process in PD is not limited to the dopaminergic system and also affects serotonergic and noradrenergic neurons. Because they can increase monoamine levels throughout the brain, monoamine reuptake inhibitors (MAUIs) represent potential therapeutic agents in PD. However, they are seldom used in clinical practice other than as antidepressants and wake-promoting agents. This review
    [Show full text]
  • Comparative Effectiveness of Second-Generation Antipsychotics
    BRITISH JOURNAL OF PSYCHIATRY (2006), 189, 433^440. doi: 10.1192/bjp.bp.105.019307 Comparative effectiveness of second-generation explained to them and who signed an informed consent statement were included. antipsychotics and haloperidol in acute Institutional review board approval was obtained for this study. {{ Pregnant or lactating women and schizophrenia patients with a medical condition in which pharmacotherapy would prove a significant ROBERT E. MCCCUE, RUBINA WAHEED, LEONEL URCUYO, clinical risk were excluded. Patients who GERALDINE ORENDAIN, MICHEL D. JOSEPH, RICHARD CHARLES had a clear history of response or lack and SYED M. HASAN of response to a particular antipsychotic drug and who, in the judgement of the treating psychiatrist, would best be Background ThereThereislittleinformation is little information Second-generation antipsychotic drugs have treated accordingly, were not entered into ononthe the comparative effectiveness of been heralded as a significant advance in the the study. Patients with a diagnosis of treatment of patients with schizophrenia. bipolar disorder, major depressive disorder second-generation antipsychotic agents. However, except for clozapine, none has or substance-induced psychotic disorder Aims Todetermine if any of five second- been conclusively shown to be superior in were also excluded. resolving the symptoms of schizophrenia. generation antipsychotics or haloperidolis Head-to-head studies are lacking. There is more effective in treating acutely ill little rational basis for selecting one over Study design patients with schizophrenia, another other than a patient’s history of Patients were admitted to one of the six schizoaffective disorder or response, lack of response or side-effects. general adult in-patient psychiatric units schizophreniform disorder.
    [Show full text]